JP2021530236A5 - - Google Patents
Info
- Publication number
- JP2021530236A5 JP2021530236A5 JP2021502833A JP2021502833A JP2021530236A5 JP 2021530236 A5 JP2021530236 A5 JP 2021530236A5 JP 2021502833 A JP2021502833 A JP 2021502833A JP 2021502833 A JP2021502833 A JP 2021502833A JP 2021530236 A5 JP2021530236 A5 JP 2021530236A5
- Authority
- JP
- Japan
- Prior art keywords
- heavy chain
- monoantibody
- sequence
- disease
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024020312A JP7737488B2 (ja) | 2018-07-20 | 2024-02-14 | Ｃｄ１９に結合する重鎖抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862701281P | 2018-07-20 | 2018-07-20 | |
| US62/701,281 | 2018-07-20 | ||
| PCT/US2019/042633 WO2020018922A1 (en) | 2018-07-20 | 2019-07-19 | Heavy chain antibodies binding to cd19 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024020312A Division JP7737488B2 (ja) | 2018-07-20 | 2024-02-14 | Ｃｄ１９に結合する重鎖抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021530236A JP2021530236A (ja) | 2021-11-11 |
| JP2021530236A5 true JP2021530236A5 (enExample) | 2022-07-26 |
| JP7439046B2 JP7439046B2 (ja) | 2024-02-27 |
Family
ID=67515196
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021502833A Active JP7439046B2 (ja) | 2018-07-20 | 2019-07-19 | Ｃｄ１９に結合する重鎖抗体 |
| JP2024020312A Active JP7737488B2 (ja) | 2018-07-20 | 2024-02-14 | Ｃｄ１９に結合する重鎖抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024020312A Active JP7737488B2 (ja) | 2018-07-20 | 2024-02-14 | Ｃｄ１９に結合する重鎖抗体 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US12202898B2 (enExample) |
| EP (2) | EP3823990B1 (enExample) |
| JP (2) | JP7439046B2 (enExample) |
| KR (2) | KR102930803B1 (enExample) |
| CN (2) | CN116769032A (enExample) |
| AU (1) | AU2019305663B2 (enExample) |
| BR (1) | BR112020024074A2 (enExample) |
| CA (1) | CA3101069A1 (enExample) |
| DK (1) | DK3823990T3 (enExample) |
| FI (1) | FI3823990T3 (enExample) |
| HR (1) | HRP20260372T1 (enExample) |
| IL (2) | IL326259A (enExample) |
| LT (1) | LT3823990T (enExample) |
| MX (1) | MX2021000708A (enExample) |
| PL (1) | PL3823990T3 (enExample) |
| PT (1) | PT3823990T (enExample) |
| SG (1) | SG11202011597RA (enExample) |
| WO (1) | WO2020018922A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250175345A (ko) | 2016-06-21 | 2025-12-16 | 테네오바이오, 인코포레이티드 | Cd3 결합 항체 |
| IL322083A (en) | 2016-08-24 | 2025-09-01 | Teneobio Inc | Non-human transgenic animals that produce modified heavy chain antibodies only |
| PE20241349A1 (es) | 2016-09-14 | 2024-07-03 | Teneobio Inc | Anticuerpos de union a cd3 |
| IL317134A (en) | 2016-12-21 | 2025-01-01 | Teneobio Inc | An antibody containing only heavy chains that binds a human B-cell maturation antigen, a pharmaceutical composition containing the same, its use in the treatment of B-cell disorders and a method for its preparation |
| CN110945026B (zh) | 2017-06-20 | 2024-03-19 | 特纳奥尼股份有限公司 | 仅有重链的抗bcma抗体 |
| KR20250007003A (ko) | 2017-06-20 | 2025-01-13 | 테네오바이오, 인코포레이티드 | 항-bcma 중쇄-단독 항체 |
| CN111683966B (zh) | 2017-12-22 | 2023-07-11 | 特尼奥生物股份有限公司 | 与cd22结合的重链抗体 |
| BR112020024074A2 (pt) | 2018-07-20 | 2021-02-17 | Teneobio, Inc. | anticorpos de cadeia pesada com ligação a cd19 |
| EP3773918A4 (en) | 2019-03-05 | 2022-01-05 | Nkarta, Inc. | CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY |
| WO2020206330A1 (en) | 2019-04-05 | 2020-10-08 | Teneobio, Inc. | Heavy chain antibodies binding to psma |
| CR20210622A (es) | 2019-06-14 | 2022-06-27 | Teneobio Inc | Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3 |
| CA3171906A1 (en) | 2020-03-16 | 2021-09-23 | University Of Southern California | Novel antigen binding domains and synthetic antigen receptors incorporating the same |
| TW202330622A (zh) | 2020-04-29 | 2023-08-01 | 美商泰尼歐生物公司 | 具有經修飾重鏈恆定區之多特異性重鏈抗體 |
| IL297601A (en) | 2020-04-29 | 2022-12-01 | Teneobio Inc | Multispecific heavy chain antibodies with modified heavy chain constant regions |
| JP7846667B2 (ja) | 2020-07-16 | 2026-04-15 | レジェンド バイオテック アイルランド リミテッド | Ｃｄ２０結合分子及びその使用 |
| IL299867A (en) * | 2020-07-16 | 2023-03-01 | Nanjing Legend Biotech Co Ltd | Cd19 binding molecules and uses thereof |
| MX2023003041A (es) | 2020-09-16 | 2023-05-09 | Amgen Inc | Métodos para administrar dosis terapéuticas de moléculas de acoplamiento a células t biespecíficas para el tratamiento de cáncer. |
| KR20230166090A (ko) * | 2021-04-06 | 2023-12-06 | 테네오바이오, 인코포레이티드 | 항-cd19 항체 및 car-t 구조체 |
| WO2024243093A2 (en) * | 2023-05-19 | 2024-11-28 | The Regents Of The University Of California | Multispecific antibodies targeting cd3 and cd22 |
| EP4566619A1 (en) | 2023-12-08 | 2025-06-11 | AvenCell Therapeutics Inc. | Targeting modules against cd19 and cd20 for use in a method for stimulating a reversed chimeric antigen receptor-mediated immune response in a mammal |
| WO2025222102A1 (en) * | 2024-04-19 | 2025-10-23 | TeneoTwo, Inc. | Therapeutic combinations of acalabrutinib and a multispecific antibody to treat b-cell malignancies |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US6066721A (en) | 1995-07-06 | 2000-05-23 | Stanford University | Method to produce novel polyketides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| WO2001024812A1 (en) | 1999-10-06 | 2001-04-12 | N.V. Nutricia | USE OF TRANSFORMING GROWTH FACTOR β AND GROWTH FACTORS IN THE TREATMENT AND PREVENTION OF DISEASES OF THE INTESTINAL MUCOSA |
| UA74798C2 (uk) | 1999-10-06 | 2006-02-15 | Байоджен Айдек Ма Інк. | Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами |
| WO2002066516A2 (en) | 2001-02-20 | 2002-08-29 | Zymogenetics, Inc. | Antibodies that bind both bcma and taci |
| GB0115256D0 (en) | 2001-06-21 | 2001-08-15 | Babraham Inst | Mouse light chain locus |
| WO2004042017A2 (en) | 2002-10-31 | 2004-05-21 | Genentech, Inc. | Methods and compositions for increasing antibody production |
| EP1585768A2 (en) | 2003-01-23 | 2005-10-19 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
| US20060008548A1 (en) | 2003-11-19 | 2006-01-12 | Invista North America S.A R.L. | Spinneret plate for producing a bulked continuous filament having a three-sided exterior cross-section and a convex six-sided central void |
| KR101151957B1 (ko) | 2004-07-22 | 2012-06-01 | 로저 킹돈 크레이그 | 결합 분자 |
| HUE025945T2 (en) * | 2005-02-15 | 2016-07-28 | Univ Duke | Anti-CD19 antibodies and their applications in oncology |
| CN101218351A (zh) * | 2005-02-15 | 2008-07-09 | 杜克大学 | 抗cd19抗体及其在肿瘤学中的应用 |
| US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
| PL2602323T3 (pl) | 2007-06-01 | 2018-06-29 | Open Monoclonal Technology, Inc. | Kompozycje i sposoby hamowania endogennych genów immunoglobin i wytwarzania transgenicznych ludzkich przeciwciał typu idiotypowego |
| US20100122358A1 (en) | 2008-06-06 | 2010-05-13 | Crescendo Biologics Limited | H-Chain-only antibodies |
| SI2315780T1 (sl) * | 2008-07-17 | 2015-11-30 | Novartis Ag | Sestavki in postopki uporabe za terapevtska protitelesa |
| MX341884B (es) | 2009-03-10 | 2016-09-07 | Biogen Ma Inc | Anticuerpos anti-antigeno de maduracion de celulas b (bcma). |
| GB0905023D0 (en) | 2009-03-24 | 2009-05-06 | Univ Erasmus Medical Ct | Binding molecules |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| WO2014122143A1 (en) | 2013-02-05 | 2014-08-14 | Engmab Ag | Method for the selection of antibodies against bcma |
| MX375669B (es) | 2014-09-26 | 2025-03-06 | Macrogenics Inc | Diacuerpos monovalentes biespecificos que son capaces de unir cd19 y cd3, y usos de los mismos. |
| CN105384825B (zh) * | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| US9914683B2 (en) * | 2016-05-26 | 2018-03-13 | X Development Llc | Fuel synthesis from an aqueous solution |
| KR20250175345A (ko) | 2016-06-21 | 2025-12-16 | 테네오바이오, 인코포레이티드 | Cd3 결합 항체 |
| IL322083A (en) | 2016-08-24 | 2025-09-01 | Teneobio Inc | Non-human transgenic animals that produce modified heavy chain antibodies only |
| PE20241349A1 (es) | 2016-09-14 | 2024-07-03 | Teneobio Inc | Anticuerpos de union a cd3 |
| IL317134A (en) | 2016-12-21 | 2025-01-01 | Teneobio Inc | An antibody containing only heavy chains that binds a human B-cell maturation antigen, a pharmaceutical composition containing the same, its use in the treatment of B-cell disorders and a method for its preparation |
| CN110945026B (zh) | 2017-06-20 | 2024-03-19 | 特纳奥尼股份有限公司 | 仅有重链的抗bcma抗体 |
| KR20250007003A (ko) | 2017-06-20 | 2025-01-13 | 테네오바이오, 인코포레이티드 | 항-bcma 중쇄-단독 항체 |
| ES2928296T3 (es) | 2017-06-30 | 2022-11-16 | Us Health | Receptores de antígenos quiméricos anti-antígenos de maduración de linfocitos B con dominios humanos |
| JP2021508479A (ja) | 2017-12-27 | 2021-03-11 | テネオバイオ， インコーポレイテッド | ヘテロ二量体特異的抗体上のｃｄ３デルタ及びｃｄ３イプシロン |
| EP3801551A4 (en) | 2018-05-24 | 2022-04-06 | Ayala Pharmaceuticals Inc. | COMPOSITIONS WITH BISFLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS AND IMMUNOTHERAPEUTICS AND METHODS OF USE THEREOF |
| BR112020024074A2 (pt) | 2018-07-20 | 2021-02-17 | Teneobio, Inc. | anticorpos de cadeia pesada com ligação a cd19 |
| CR20210622A (es) | 2019-06-14 | 2022-06-27 | Teneobio Inc | Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3 |
| IL297601A (en) | 2020-04-29 | 2022-12-01 | Teneobio Inc | Multispecific heavy chain antibodies with modified heavy chain constant regions |
-
2019
- 2019-07-19 BR BR112020024074-5A patent/BR112020024074A2/pt unknown
- 2019-07-19 EP EP19749123.6A patent/EP3823990B1/en active Active
- 2019-07-19 KR KR1020207034987A patent/KR102930803B1/ko active Active
- 2019-07-19 PT PT197491236T patent/PT3823990T/pt unknown
- 2019-07-19 JP JP2021502833A patent/JP7439046B2/ja active Active
- 2019-07-19 HR HRP20260372TT patent/HRP20260372T1/hr unknown
- 2019-07-19 SG SG11202011597RA patent/SG11202011597RA/en unknown
- 2019-07-19 CA CA3101069A patent/CA3101069A1/en active Pending
- 2019-07-19 US US17/260,213 patent/US12202898B2/en active Active
- 2019-07-19 IL IL326259A patent/IL326259A/en unknown
- 2019-07-19 KR KR1020267005215A patent/KR20260036383A/ko active Pending
- 2019-07-19 DK DK19749123.6T patent/DK3823990T3/da active
- 2019-07-19 CN CN202310539593.8A patent/CN116769032A/zh active Pending
- 2019-07-19 PL PL19749123.6T patent/PL3823990T3/pl unknown
- 2019-07-19 AU AU2019305663A patent/AU2019305663B2/en active Active
- 2019-07-19 MX MX2021000708A patent/MX2021000708A/es unknown
- 2019-07-19 LT LTEPPCT/US2019/042633T patent/LT3823990T/lt unknown
- 2019-07-19 EP EP25219867.6A patent/EP4714502A2/en active Pending
- 2019-07-19 CN CN201980035712.8A patent/CN112351997B/zh active Active
- 2019-07-19 WO PCT/US2019/042633 patent/WO2020018922A1/en not_active Ceased
- 2019-07-19 FI FIEP19749123.6T patent/FI3823990T3/fi active
-
2020
- 2020-11-26 IL IL279010A patent/IL279010B1/en unknown
-
2024
- 2024-02-14 JP JP2024020312A patent/JP7737488B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021530236A5 (enExample) | ||
| JP2022537931A5 (enExample) | ||
| JP2022505445A5 (enExample) | ||
| JP2024507540A5 (enExample) | ||
| JP2023526774A5 (enExample) | ||
| AU2014228962B2 (en) | Multimerization technologies | |
| JP7570338B2 (ja) | クローディン６抗体及びその使用 | |
| US20210188989A1 (en) | Anti-4-1bb antibodies and methods of making and using thereof | |
| JP2022526595A5 (enExample) | ||
| RU2004121673A (ru) | Человеческие полипептиды, вызывающие или опосредующие лизис клеток, включая клетки лимфоидных опухолей | |
| JP2024062992A5 (enExample) | ||
| JP2024508808A5 (enExample) | ||
| JP2023517753A5 (enExample) | ||
| JP2024514107A5 (enExample) | ||
| RU99101121A (ru) | Полипептиды, способные к образованию антигенсвязывающих структур со специфичностью к резус-d-антигенам, днк, кодирующая их, способы их получения и применение | |
| JP2024516098A5 (enExample) | ||
| WO2020172641A1 (en) | Artificial immunosurveillance chimeric antigen receptor and cells expressing the same | |
| JP2026510999A (ja) | Ｃｄ１９／ｃｄ３８多重特異性抗体 | |
| JP2022516301A (ja) | Ｃｄ１３７アゴニスト性抗体とその使用 | |
| CN104105706A (zh) | 用于治疗疾病的抗人sema4A抗体 | |
| JP2025530888A5 (enExample) | ||
| JPH05503687A (ja) | 自己免疫疾患の治療 | |
| CN114685659B (zh) | Cd22特异性人源化抗体及利用其的嵌合抗原受体 | |
| WO2023045370A1 (zh) | 靶向tigit的单克隆抗体 | |
| CN116023496A (zh) | 一种制备通用型car-t细胞的方法及其应用 |